Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RxSight, Inc.RXST · Entity 1226 | Chief Financial Officer | September 05, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RxSight, Inc.
Report date September 05, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2036-01-11 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-05 · Disposition to issuer · Disposed 258,770 · Balance 0 F2: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share. F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 258,770 |
Reported balance
After 2026-09-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-05 · Grant · Acquired 258,770 · Balance 258,770 F2: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share. F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date.
F2: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share.
F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2026 Filed Sep 10, 2026 00:55 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 258,770 | Not disclosed Strike: $6.38 | Not disclosed |
DisclosureSEC source: 0001193125-26-386841 · ownership.xml · derivative · entry 2 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,770 Underlying: Common Stock · 258,770 shares Expires 2033-09-04 F2 · price: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. Read SEC document |
| September 05, 2026 Filed Sep 10, 2026 00:55 UTC | RxSight, Inc. RXST · Entity 1226 | Disposition to issuerStock Option (right to buy) · Derivative | 258,770 | Not disclosed Strike: $10.09 | Not disclosed |
DisclosureSEC source: 0001193125-26-386841 · ownership.xml · derivative · entry 1 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 258,770 shares Expires 2036-01-11 F2 · price: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share. F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 01:35 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 7,765 | $6.96 | $54,044.40 |
DisclosureSEC source: 0001193125-26-380713 · ownership.xml · nonDerivative · entry 2 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,049 F2 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| August 31, 2026 Filed Sep 3, 2026 01:35 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionRestricted Stock Unit · Derivative | 20,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-380713 · ownership.xml · derivative · entry 3 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,646 Underlying: Common Stock · 20,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period. Read SEC document |
| August 31, 2026 Filed Sep 3, 2026 01:35 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 20,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-380713 · ownership.xml · nonDerivative · entry 1 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 28, 2026 Filed Mar 4, 2026 01:24 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionRestricted Stock Unit · Derivative | 20,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089508 · ownership.xml · derivative · entry 3 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,087 Underlying: Common Stock · 20,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period. Read SEC document |
| February 28, 2026 Filed Mar 4, 2026 01:24 UTC | RxSight, Inc. RXST · Entity 1226 | Tax withholdingCommon Stock | 8,068 | $7.61 | $61,397.48 |
DisclosureSEC source: 0001193125-26-089508 · ownership.xml · nonDerivative · entry 2 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,373 Read SEC document |
| February 28, 2026 Filed Mar 4, 2026 01:24 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 20,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-089508 · ownership.xml · nonDerivative · entry 1 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 12, 2026 Filed Jan 30, 2026 21:14 UTC | RxSight, Inc. RXST · Entity 1226 | GrantRestricted Stock Unit · Derivative | 163,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-031826 · ownership.xml · derivative · entry 2 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,528 Underlying: Common Stock · 163,528 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award will vest on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award will vest on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period. Read SEC document |
| January 12, 2026 Filed Jan 30, 2026 21:14 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 258,770 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001193125-26-031826 · ownership.xml · derivative · entry 1 Wilterding Mark · CIK 0002107187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,770 Underlying: Common Stock · 258,770 shares Expires 2036-01-11 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.